Clinical-stage biopharmaceutical company MacroGenics has entered into a global collaboration and license agreement with US-based biotechnology company Janssen Biotech to develop MGD015, a preclinical bispecific molecule.

MGD015 uses MacroGenics’ dual-affinity re-targeting (DART) platform to simultaneously target CD3 and an undisclosed tumour target, for the possible treatment of a wide range of hematological malignancies and solid tumours.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MacroGenics has revealed that MGD015 is capable of killing these targeted CD3 both in vitro and in vivo.

Under the deal, as well as subject to the termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act, MacroGenics will receive an upfront license fee worth $75m.

"MGD015 is a promising product candidate that employs MacroGenics’ proprietary DART platform to enable a potent redirected T-cell killing mechanism with ‘off-the-shelf’ convenience."

Janssen, on the other hand, will have to complete IND-enabling activities, along with being responsible for further clinical development of MGD015.

See Also:

MacroGenics also expects to receive up to an additional $665m in regulatory, clinical and commercialisation milestone payments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MacroGenics president and CEO Scott Koenig said: "MGD015 is a promising product candidate that employs MacroGenics’ proprietary DART platform to enable a potent redirected T-cell killing mechanism with ‘off-the-shelf’ convenience.

"This approach is already being evaluated in five other clinical-stage DART programmes.

"Janssen represents the ideal partner for MGD015, given its track record of successfully developing and commercialising transformative oncology therapies."

After its commercialisation, MacroGenics will be able to receive double-digit royalties on any global net sales, as well as promote MGD015 in the US in collaboration with Janssen.